GLUE Live signals | Maximize Profits with Getagraph.com

SELL 101064 min ago

@ $4.87

Issued: 9 Feb 2024 @ 10:05

Return: 19.25%

Previous signal: Feb 7 - 14:34

Previous signal: Buy

Return: 3.99 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 15:28):

Stats
Today's Volume	76 543.00
Average Volume	135 233
Market Cap	291.40M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $-0.560 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.21
ATR14	$0.0270 (0.46%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-02	Warmuth Markus	Buy	346 000	Stock Option (Right to Buy)
2024-01-02	Wallace Owen B.	Buy	119 000	Stock Option (Right to Buy)
2024-01-02	Jones Jullian G	Buy	79 000	Stock Option (Right to Buy)
2024-01-02	Janku Filip	Buy	121 000	Stock Option (Right to Buy)
2024-01-02	Nickson Philip	Buy	109 000	Stock Option (Right to Buy)

INSIDER POWER
92.69
Last 98 transactions
Buy: 57 206 836 \| Sell: 164 598 288

Volume Correlation

Long: -0.17 (neutral)

Short: 0.66 (moderate)

Signal:(72.51) Neutral

Monte Rosa Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Monte Rosa Therapeutics, Correlation - Currency/Commodity

0.08
( neutral )

-0.20
( neutral )

0.00
( neutral )

0.29
( neutral )

-0.78
( moderate negative )

-0.12
( neutral )

Monte Rosa Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-6.22M (0.00 %)
EPS:	$-2.63

Q4	2023
Revenue:	$0
Gross Profit:	$-1.85M (0.00 %)
EPS:	$-0.580

Q3	2023
Revenue:	$0
Gross Profit:	$-1.83M (0.00 %)
EPS:	$-0.700

Q2	2023
Revenue:	$0
Gross Profit:	$-1.39M (0.00 %)
EPS:	$-0.710

Financial Reports:

No articles found.

Monte Rosa Therapeutics,

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.